Asia Pacific Ophthalmology Therapeutics Market Research Report – Segmented By Indication, End User and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis, Size, Share, Growth, Trends, Forecast (2024 to 2029)

Updated On: June, 2024
ID: 1046
Pages: 145

APAC Ophthalmology Therapeutics Market Size (2023 to 2028)

The Ophthalmology Therapeutics Market in APAC was worth USD 5.31 billion in 2023 and is estimated to grow at a CAGR of 8.5%, to reach USD 7.98 billion by 2028.

Ophthalmology is the branch of medicine that deals with the eye's anatomy, physiology, and diseases. Recent advancements in genetics and stem cell biology have brought several changes to the Ophthalmology Therapeutics Market.

The growing prevalence of vision impairment drives Asia Pacific Ophthalmology Therapeutics. According to a recent update by WHO, the prevalence of visual impairment is nearly 285 million globally. Of these, 246 million people have moderate to severe visual impairment. South-East Asia and the Western Pacific accounted for 73% of the total visual impairments. Other major factors driving the growth of the market include increasing awareness about the importance of detecting ophthalmic diseases as early as possible and efficient diagnostic tools.

However, stringent regulatory framework and lack of reimbursement policies are restraining the growth of the market.

This research report on the Asia Pacific Ophthalmology Therapeutics Market has been segmented and sub-segmented Market into the following categories:

By Indication: 

  • Glaucoma
  • Dry Eye Syndrome
  • Diabetic Retinopathy
  • Retinal Vein Occlusion
  • Age-related Macular Degeneration
  • Macular Edema
  • Allergic Conjunctivitis

By End User: 

  • Hospitals
  • Eye Clinics
  • Diagnostic Centres
  • Patients

By Country: 

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Geographically, Asia-Pacific is the fastest-growing region with a CAGR of xx% during the forecast period. Within Asia-Pacific, Japan is the largest market for Opthalmology therapeutics accounting for a share of approximately 45%, followed by China. Glaucoma is the largest indication segment accounting for a share of approximately XX%.

Prominent companies in the APAC Ophthalmology Therapeutics Market are Pfizer Inc., Allergan Inc., Alcon Inc., Merck & co. Inc., Roche Valeant, Regeneron, Santen, Bayer, Senju, Lpath, and Eye Gate Pharmaceuticals.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample